Online inquiry

IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6015MR)

This product GTTS-WQ6015MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL12B gene. The antibody can be applied in Psoriatic arthritis (PSA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002187.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3593
UniProt ID P29460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6015MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10885MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ6728MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ14736MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ15704MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ13175MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ57MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ9835MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ13278MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06252616
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW